Evidence map›Paper›PMID 29149425›Full record

ArticleInternational journal of hematology2018

Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.

Keiji Nogami, Midori Shima, Katsuyuki Fukutake, Teruhisa Fujii, Masashi Taki, Tadashi Matsushita, Satoshi Higasa, Tetsuji Sato, Michio Sakai, Morio Arai and 4 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Keiji NogamiDepartment of Pediatrics, Nara Medical University, Kashihara, Japan. roc-noga@naramed-u.ac.jp.
Midori ShimaDepartment of Pediatrics, Nara Medical University, Kashihara, Japan.
Katsuyuki FukutakeDepartment of Laboratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan.
Teruhisa FujiiDepartment of Hematology and Oncology, Hiroshima University Hospital, Hiroshima, Japan.
Masashi TakiDepartment of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Japan.
Tadashi MatsushitaDepartment of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.
Satoshi HigasaDivision of Hematology, Hyogo College of Medicine Hospital, Nishinomiya, Japan.
Tetsuji SatoDepartment of Pediatrics, University of Occupational and Environmental Health, Kitakyushu, Japan.
Michio SakaiDepartment of Pediatrics, Munakata Suikokai General Hospital, Fukutsu, Japan.
Morio AraiDepartment of Medical Affairs, Baxalta Japan Ltd., Tokyo, Japan.
Haruhiko UchikawaDepartment of Clinical Development Operations, Baxalta Japan Ltd., Tokyo, Japan.
Werner EnglShire, Vienna, Austria.
Brigitt AbbuehlShire, Vienna, Austria.
Barbara A KonklePuget Sound Blood Center, University of Washington School of Medicine, Seattle, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The authors would like to correct the error in Table 2 in the original publication of the article. The "Blood type" is not described in any part of "Results" and "Discussion" and had no impact on the conclusion hence the bottom of the table is removed.

Identifiers

PMID29149425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.